MDGL (Madrigal Pharmaceuticals) Momentum Rank: 10 (As of Aug. 31, 2026) — 150% Above Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MDGL Madrigal Pharmaceuticals Inc MDGL
31 GF Score
Price $540.03
! 4 Warning Signs
View Full Analysis

What is Madrigal Pharmaceuticals Momentum Rank?

Madrigal Pharmaceuticals MDGL +1.02% 31 Momentum Rank is 10 as of Aug. 31, 2026, which is 150% above its 10-year median of 4.00. GuruFocus rates MDGL with a GF Score™ of 31/100. The stock has 4 warning signs investors should review.

Madrigal Pharmaceuticals has the Momentum Rank of 10.

Momentum Rank measures the strength and persistence of a stock's price movement over time, rated on a scale of 1 to 10.

For Momentum Rank, we considered the residual momentum concept that was widely studied by Blitz and his colleagues as well as by Nobel Prize laureates Fama and French. However, we did not find any significant differences in the performances of stocks with different ranks of residual momentum. Therefore, we use traditional momentum instead.

Momentum Rank is determined using the standardized momentum ratio and other momentum indicators. The standardized momentum ratio is the average of the performances from 12 months ago to 1 month ago and 6 months ago to 1 month ago, divided by the beta of the stock over the past 12 months. To calculate the momentum ratio today, we would use the average of the two performance numbers.

For momentum, we found that stock price performance does not have a monotonic correlation with the momentum ratio. The stocks with the highest momentum ratios perform worse than those at about the 70th percentile. Therefore, for the momentum rank, we ranked the stocks at about the 70th percentile of the momentum ratio as the highest at 10.

A higher score reflects strong price momentum and indicates greater potential for superior performance. Conversely, a lower score indicates that momentum is either too high or too low, and stocks tend to underperform.

Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.

Madrigal Pharmaceuticals Momentum Rank Related Terms

MDGL vs CORT, BMRN, ARWR: Momentum Rank Comparison

For the Biotechnology subindustry, Madrigal Pharmaceuticals's Momentum Rank, along with its competitors' market caps and Momentum Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Madrigal Pharmaceuticals Momentum Rank vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Madrigal Pharmaceuticals's Momentum Rank distribution charts can be found below:

* The bar in red indicates where Madrigal Pharmaceuticals's Momentum Rank falls into.


MDGL
31GF Score
Madrigal Pharmaceuticals Inc MDGL
Momentum Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Momentum Rank →
What does a Momentum Rank of 10 mean?
Madrigal Pharmaceuticals (MDGL) has a Momentum Rank of 10 as of Aug. 31, 2026. Momentum Rank is determined using the standardized momentum ratio, measuring the speed and velocity of price changes in a stock. View historical data on Madrigal Pharmaceuticals and its competitors. This is 150% above median its historical median of 4.00. Over the past decade, Madrigal Pharmaceuticals' Momentum Rank has ranged from 1.00 to 10.00.
Is Madrigal Pharmaceuticals' Momentum Rank too high?
Madrigal Pharmaceuticals' current Momentum Rank of 10 is 150% above median its 10-year median of 4.00. Over the past 10 years, this metric has ranged from a low of 1.00 to a high of 10.00. Overall, Madrigal Pharmaceuticals has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does Madrigal Pharmaceuticals' Momentum Rank compare to CORT and BMRN?
Madrigal Pharmaceuticals' Momentum Rank of 10 can be compared against companies in the Biotechnology industry. Historically, Madrigal Pharmaceuticals' own Momentum Rank has ranged from 1.00 to 10.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Momentum Rank for a Biotechnology company?
A good Momentum Rank depends on the Biotechnology industry context. However, Momentum Rank should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Momentum Rank mean?
A high Momentum Rank can signal that a stock is expensive relative to its fundamentals. Momentum Rank is determined using the standardized momentum ratio, measuring the speed and velocity of price changes in a stock. View historical data on Madrigal Pharmaceuticals and its competitors. Madrigal Pharmaceuticals's current Momentum Rank is 10, which is 150% above median its own 10-year median of 4.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Madrigal Pharmaceuticals stock overvalued right now?
Madrigal Pharmaceuticals (MDGL) has a current Momentum Rank of 10. The current Momentum Rank is 10, which is 150% above median its 10-year median of 4.00. Madrigal Pharmaceuticals' overall GF Score™ is 31/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Momentum Rank calculated?
Momentum Rank is calculated from a company's financial statements. For Madrigal Pharmaceuticals (MDGL), the current Momentum Rank is 10 as of Aug. 31, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Madrigal Pharmaceuticals Business Description

Address 200 Barr Harbor Drive, Suite 200, Four Tower Bridge, West Conshohocken, PA, USA, 19428
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, liver cancer, need for liver transplantation and premature mortality. Its medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor beta agonist designed to target key underlying causes of MASH.
31GF Score

Get the complete analysis for MDGL

Momentum Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$540.03
Price